Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Farmers Insurance
Baxter
US Department of Justice
Cipla
Queensland Health
Johnson and Johnson
Boehringer Ingelheim
McKesson
Covington

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202001

« Back to Dashboard

NDA 202001 describes PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, which is a drug marketed by Aurobindo Pharma Ltd, Macleods Pharms Ltd, Mylan, Sandoz, Teva Pharms Usa, and Torrent Pharms Ltd, and is included in six NDAs. It is available from nine suppliers. Additional details are available on the PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE profile page.

The generic ingredient in PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE is metformin hydrochloride; pioglitazone hydrochloride. There are forty-eight drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.
Summary for 202001
Suppliers and Packaging for NDA: 202001
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 202001 ANDA TORRENT PHARMACEUTICALS LIMITED 13668-280 13668-280-74 100 TABLET in 1 CARTON (13668-280-74)
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 202001 ANDA TORRENT PHARMACEUTICALS LIMITED 13668-280 13668-280-05 500 TABLET in 1 BOTTLE (13668-280-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength500MG;EQ 15MG BASE
Approval Date:Feb 13, 2013TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength850MG;EQ 15MG BASE
Approval Date:Feb 13, 2013TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
Queensland Health
UBS
Daiichi Sankyo
Novartis
Citi
Boehringer Ingelheim
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot